Product Details
|
98319-26-7 Name |
|
|
Name |
Finasteride |
|
Synonym |
(5alpha,17beta)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide;17beta-(n-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one;4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5-alpha,17-be;4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta;l-652,931;mk-0906;n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide;(5alpha,17beta)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide |
|
98319-26-7 Biological Activity |
|
|
Description |
Finasteride is an orally active testosterone 5-alpha-reductase inhibitor (Ki= 10 nM). Target: 5-alpha ReductaseApproved: 1992Finasteride, a synthetic 4-azasteroid antiandrogen compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). Finasteride is used in the treatment of prostate cancer, benign prostatic hyperplasia, and androgenetic alopecia (male pattern baldness). In benign prostatic hyperplasia, finasteride inhibits 5alpha-reductase activity in epithelium for Ki of 10 nM, significantly lower than in stroma (Ki = 33nM) [1]. |
|
Related Catalog |
Signaling Pathways >> Metabolic Enzyme/Protease >> 5 alpha Reductase Research Areas >> Cancer |
|
References |
[1]. Weisser, H. and M. Krieg, In vitro inhibition of androstenedione 5alpha-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia. J Steroid Biochem Mol Biol, 1998. 67(1): p. 49-55. |
|
98319-26-7 Chemical & Physical Properties |
|
|
Melting point |
253 °C |
|
Boiling point |
576.6±50.0 °C at 760 mmHg |
|
Density |
1.1±0.1 g/cm3 |
|
Molecular Formula |
C23H36N2O2 |
|
Molecular Weight |
372.544 |
|
Flash Point |
177.4±30.3 °C |
|
PSA |
58.20000 |
|
LogP |
3.24 |
|
Exact Mass |
372.277679 |
|
Vapour Pressure |
0.0±1.6 mmHg at 25°C |
|
Index of Refraction |
1.524 |
|
Storage condition |
Store at RT |
|
Solubility |
DMSO: 32 mg/mL, soluble |
|
98319-26-7 Description |
|
Finasteride, a novel 4-azasteroid, is a breakthrough in the treatment and control of benign prostatic hyperplasia. Mechanistically, it inhibits the prostatic-specific enzyme 5-alpha reductase, thereby decreasing the conversion of testosterone to dihydrotestosterone. It is reportedly effective in reducing urinary symptoms and prostatic volume and increasing maximal urinary flow rate. Finasteride is also being investigated as a treatment for prostatic cancer. |
|
98319-26-7 Uses |
|
Finasteride is an antialopecia agent that Inhibitor of 5α-reductase, the enzyme which converts testosterone to the more potent androgen, 5α-dihydrotestosterone. It is used to treatment of benign prostatic hyperplasia and androgenetic alopecia. |
